Medtronic has received US Food and Drug Administration (FDA) approval for its iPro2, a next-generation continuous glucose monitoring system.

The iPro2 device allows physicians to reveal hypoglycaemic and hyperglycaemic glucose excursions can lead to dangerous health complications in patients with diabetes.

The system will help identify nocturnal hypoglycaemic or hyperglycaemic following meals, allowing users to make therapy adjustments that can result in better glucose control.

iPro2 records and stores up to 288 glucose readings a day, and provides clinicians with an insight into how diet, medication and daily activities affect their patients’ glucose levels.